Pirfenidone: A potential therapeutic option in the treatment of liver fibrosis

Clinical and Experimental Pharmacology and Physiology

Volumn 36, Issue 10, 2009, Pages 961-962

  Grizzi, F ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; RETINOL;

DRUG MECHANISM; HUMAN; LIVER CELL; LIVER FIBROSIS; MYOFIBROBLAST; NONHUMAN; NOTE; STELLATE CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG EVALUATION, PRECLINICAL; HUMANS; LIVER CIRRHOSIS; MICE; MICE, INBRED BALB C; PYRIDONES; RATS; RATS, WISTAR;

EID: 72449173932     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05262.x     Document Type: Note

References (20)

1. Henderson NC, Forbes SJ. Hepatic fibrogenesis. From within and outwith. Toxicology 2008; 254: 130-135
2. Bataller R, Brenner DA. Liver fibrosis. J. Clin. Invest. 2005; 115: 209-218
3. Iredale J. Defining therapeutic targets for liver fibrosis: Exploiting the biology of inflammation and repair. Pharmacol. Res. 2008; 58: 129-136
4. Jiao J, Friedman. SL, Aloman C. Hepatic fibrosis. Curr. Opin. Gastroenterol. 2009; 25: 223-229
5. Atzori L, Poli G, Perra A. Hepatic stellate cell: A star cell in the liver. Int. J Biochem. Cell Biol. 2009; 41: 1639-1642
6. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction, and reality. J. Cell Mol. Med. 2007; 11: 1031-1051 (Pubitemid 350037048)
7. Desmet VJ, Roskams T. Cirrhosis reversal. A duel between dogma and myth. J. Hepatol. 2004; 40: 860-867 (Pubitemid 38507370)
8. Gressner OA, Weiskirchen R, Gressner AM. Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comp. Hepatol. 2007; 6: 7. (Pubitemid 47505515)
9. Rockey DC. Current and future anti-fibrotic therapies for chronic liver disease. Clin. Liver Dis. 2008; 12: 939-962
10. Salazar-Montes A, Ruiz-Corro L, López-Reyes A, Castrejón-Gómez E, Armendariz-Borunda J. Potent antioxidant role of pirfenidone in experimental cirrhosis. Eur. J. Pharmacol. 2008; 595: 69-77.
11. Armendáriz-Borunda J, Islas-Carbajal. MC, Meza-García E et al. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut 2006; 55: 1663-1665 (Pubitemid 44629221)
12. Garcia L, Hernández I, Sandoval A et al. Pirfenidone effectively reverses experimental liver fibrosis. J. Hepatol. 2002; 37: 797-805. (Pubitemid 35404219)
13. Di Sario A, Bendia E, Svegliati Baroni G et al. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J. Hepatol. 2002;37:584-591 (Pubitemid 35305537)
14. Tada S, Nakamuta M, Enjoji M et al. Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin. Exp. Pharmacol. Physiol. 2001; 28: 522-527 (Pubitemid 32588427)
15. Zhao XY, Zeng X, Li XM, Wang TL, Wang BE. Pirfenidone effectively inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells. Clin. Exp. Pharmacol. Physiol. 2009; 36: 963-968
16. Sun MA, Wang BE, Annoni G, Degli Esposti S, Biempica L, Zern. MA. Two rat models of hepatic fibrosis. A morphologic and molecular comparison. Lab. Invest. 1990; 63:467-475 (Pubitemid 20368726)
17. Standish RA, Cholongitas E, Dhillon A, Burroughs AK,Dhillon AP. An appraisal of the histopathological assessment of liver fibrosis. Gut 2006; 55: 569-578
18. Dioguardi N, Grizzi F, Fiamengo B, Russo C. Metrically measuring liver biopsy. A chronic hepatitis B and C computer-aided morphologic description. World J. Gastroenterol. 2008; 14: 7335-7344
19. Castora L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral, hepatitis. J. Viral Hepat. 2009; 16: 300-314
20. Popov Y, Schuppan D. Targeting liver fibrosis: Strategies for development and validation of antifibrotic therapies. Hepatohgy 2009. Epub 15 June 2009; doi: 10.1002/hep.23123.